The federal regulatory agency that exists to protect consumers and promote competition across the economy is newly focused on patients and clinicians as well as taxpayers.
Novo Nordisk will be selling the new 7.2-mg dose under the brand name Wegovy HD. The FDA's decision fell under a new pilot program intended to grant certain companies improved access and quicker approvals.
The Cardiovascular Business Forty Under 40 Class of 2026 represents an accomplished group of clinicians, researchers, entrepreneurs and administrators who are redefining what cardiovascular leadership looks like under the age of 40.
Market forces like competition cannot stem the urge to merge among and between payers and providers, so neither will they staunch the price hikes in premiums.
The hope is that the new service will open the door for patients to undergo treatment and diagnostic exams locally instead of having to travel long distances.
